News Release
Creo Medical Group "looking very well" - Proactive Research Analyst
Creo Medical Group PLC
Proactive Research Analyst Daniel Appiah gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Creo recently announced that the medical device company's Speedboat Inject product was used for the first time in an upper gastrointestinal (GI) procedure in Europe, a major milestone for the business. Appiah says Creo is "looking very well" and gives his take on what recent developments are likely to mean for the company's financials. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
July 03, 2023 09:09 AM Eastern Daylight Time
Video
News Release
Prenetics Global signs "transformational" $200mln deal to create cancer screening JV
Prenetics Global Ltd
Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com
June 30, 2023 08:00 AM Eastern Daylight Time
Video
News Release
Xeris Biopharma CEO reveals impact of CSO's departure and exciting future plans
Xeris Biopharma Holdings
Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions to a consulting role with Xeris. Edick said the impact of Dr. Prestrelski stepping down as the CSO will be negligible as Xeris Biopharma has transitioned from a research and development company to primarily a commercial business with development activities. Edick adds that Xeris Biopharma will retain Dr. Prestrelski as a consultant for the next year or two as needed. Edick also expressed excitement for Dr. Prestrelski's future endeavours, potentially starting another company focused on peptides and research which aligns more with his interests, and emphasized that the rest of the company is operating well with a healthy business, three growing products, partnerships with Big Pharma, and another product in the pipeline. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com
June 29, 2023 04:19 PM Eastern Daylight Time
Video
News Release
NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2
NanoViricides
NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies. Diwan told Proactive the Phase 1a/1b safety and efficacy clinical trial began June 17th and is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. The trial will use patients with mild to moderate COVID-19 to assess indication of efficacy. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
June 29, 2023 03:00 PM Eastern Daylight Time
Video
News Release
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
RenovoRx Inc
RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an overview of the lead candidate product RenovoGem that he has presented to the Congress, before going on to explain where the product is in its development cycle. He says the product has met with "a lot of enthusiasm" so far and reveals his hopes of getting early approval from the FDA "next year or early in 2025." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com
June 29, 2023 11:42 AM Eastern Daylight Time
Video
News Release
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma PLC
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
June 29, 2023 03:54 AM Eastern Daylight Time
Video
News Release
TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate
TransCode Therapeutics Inc
TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com
June 28, 2023 03:49 PM Eastern Daylight Time
Video
News Release
Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology
Tonix Pharmaceuticals
Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the recent publication of the company's Phase 3 study on TNX-102 SL for fibromyalgia management in the American College of Rheumatology. Lederman said the article outlined how the study's results showed improvements in widespread pain and fatigue, which are significant symptoms of fibromyalgia. He explains that TNX-102 SL, a sublingual tablet taken at bedtime, targets sleep quality to enhance overall fibromyalgia symptoms. With the upcoming confirmatory Phase 3 trial results, Lederman said Tonix aims to file a new drug application for TNX-102 SL. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com
June 28, 2023 03:21 PM Eastern Daylight Time
Video
News Release
Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial
Atossa Therapeutics Inc
Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, achieving a 30 percent enrollment rate within two months of the trial commencing. The I-SPY 2 TRIAL is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium. The (Z)-endoxifen treatment arm, which is expected to enroll approximately 20 patients, is part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP). Patients will receive 10 mg of (Z)-endoxifen daily for up to 24 weeks prior to surgery. Currently, there are 41 I-SPY 2 sites, all of which have the EOP program open. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
June 28, 2023 01:03 PM Eastern Daylight Time
Video
